2019
DOI: 10.1016/j.jss.2019.01.046
|View full text |Cite
|
Sign up to set email alerts
|

The Contrary Effects of Sirt1 on MCF7 Cells Depend on CD36 Expression Level

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
3
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(5 citation statements)
references
References 34 publications
2
3
0
Order By: Relevance
“…The lack of protection is probably related to the active concentration of this antimicrobial peptide [ 24 ]. These results are consistent with those reported by Yao and Duan, who reported that high concentrations inhibited growth, but low concentrations promoted cell growth [ 25 26 ]. Therefore, a suitable concentration range must be determined.…”
Section: Discussionsupporting
confidence: 93%
“…The lack of protection is probably related to the active concentration of this antimicrobial peptide [ 24 ]. These results are consistent with those reported by Yao and Duan, who reported that high concentrations inhibited growth, but low concentrations promoted cell growth [ 25 26 ]. Therefore, a suitable concentration range must be determined.…”
Section: Discussionsupporting
confidence: 93%
“…Therefore, high levels of SIRT1 may cause cell cycle arrest. More interestingly, SIRT1 overexpression was found to inhibit cell proliferation in the MCF-7 cell line [59] , which is in good agreement with this model. In summary, when SIRT1 is overexpressed, lower DNA damage drives P53 periodic pulsing-regulated cell cycle arrest, and higher DNA damage drives P53 monotonic increase and apoptosis.…”
Section: Resultssupporting
confidence: 84%
“…It also interacts with transcription factors or co-factors, including p53, FOXO family member, NF-κB, myoblast determination protein 1, nuclear receptor corepressor, p300 and peroxisome proliferator-activated receptor γ coactivator 1-α, and regulates their transcriptional activity. SIRT1 inhibitors exhibit antitumor activity, which has been observed in cells from breast, thyroid, lung, pancreatic, prostate, hepatitis and colon cancer (17)(18)(19)(20)(21). Moreover, SIRT1 has effective antitumor activity against hematological malignancies, such as T/B-cell lymphoma, chronic myeloid leukemia (CML), leukemia and other hematological malignancies (11,(22)(23)(24)(25)(26).…”
Section: Discussionmentioning
confidence: 99%